Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

BACKGROUND: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EBioMedicine
Autori principali: Kaoutari, Abdessamad El, Fraunhoffer, Nicolas A, Hoare, Owen, Teyssedou, Carlos, Soubeyran, Philippe, Gayet, Odile, Roques, Julie, Lomberk, Gwen, Urrutia, Raul, Dusetti, Nelson, Iovanna, Juan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8054161/
https://ncbi.nlm.nih.gov/pubmed/33862584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2021.103332
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi